Controversies in oncology: which adjuvant endocrine therapy is to be given to premenopausal patients with hormone receptor-positive breast cancer?

ESMO Open. 2018 Mar 29;3(3):e000350. doi: 10.1136/esmoopen-2018-000350. eCollection 2018.

Authors

Matteo Lambertini^{1

2}, Giulia Viglietti², Evandro de Azambuja¹

Affiliations

¹ Department of Medicine, Institut Jules Bordet, Université Libre de Bruxelles (ULB), Brussels, Belgium.
² Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles (ULB), Brussels, Belgium.

No abstract available

Keywords: aromatase inhibitor; breast cancer; ovarian function suppression; premenopausal; tamoxifen.

Publication types

Editorial